Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 7, 2020

Study Completion Date

July 15, 2020

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Pazopanib

Pazopanib 800mg day to be given continuously until disease progression.

Trial Locations (9)

Unknown

Beaumont Hospital, Dublin

Mater Misericordiae University Hospital, Dublin

Mater Private Hospital, Dublin

Cork University Hospital, Cork

The Adelaide & Meath Hospital Dublin incorporating the National Children's Hospital, Dublin

Galway University Hospital, Galway

Mid-Western Regional Hospital, Limerick

Waterford Regional Hospital, Waterford

Karolinska University Hospital, Stockholm

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Cancer Trials Ireland

NETWORK

NCT01566747 - Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | Biotech Hunter | Biotech Hunter